Native Antigen

Upper Heyford, United Kingdom Founded: 2010 • Age: 16 yrs Acquired By LGC
Development and manufacture of native and recombinant viral and bacterial antigens

About Native Antigen

Native Antigen is a company based in Upper Heyford (United Kingdom) founded in 2010 was acquired by LGC in July 2020.. Native Antigen has raised $1.1 million across 5 funding rounds from investors including Mercia and LGC. The company has 28 employees as of July 31, 2020. Native Antigen offers products and services including Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits. Native Antigen operates in a competitive market with competitors including Nautilus Biotechnology, Somalogic, ProteinSimple, Amunix and Dynamic Biosensors, among others.

  • Headquarter Upper Heyford, United Kingdom
  • Employees 28 as on 31 Jul, 2020
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name The Native Antigen Company Limited
  • Date of Incorporation 23 Sep, 2010
  • Jurisdiction TEDDINGTON, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.1 M (USD)

    in 5 rounds

  • Latest Funding Round
    $179.72 K (USD), Series A

    Jun 03, 2015

  • Investors
    Mercia

    & 1 more

  • Employee Count
    28

    as on Jul 31, 2020

  • Acquired by
    LGC

    (Jul 09, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Native Antigen

Native Antigen offers a comprehensive portfolio of products and services, including Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Products for detecting viral and bacterial pathogens in research.

Simulated particles for vaccine and diagnostic development.

Kits for antibody detection in disease testing.

Substances for studying bacterial infections.

Kits for labeling proteins in assays.

Funding Insights of Native Antigen

Native Antigen has successfully raised a total of $1.1M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $179.72 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series A — $179,723
  • First Round

    (05 Dec 2010)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2015 Amount Series A - Native Antigen Valuation

investors

Nov, 2014 Amount Series A - Native Antigen Valuation

investors

Apr, 2013 Amount Series A - Native Antigen Valuation Mercia
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Native Antigen

Native Antigen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Mercia and LGC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Investment management services are provided by Mercia to various clients.
Founded Year Domain Location
Molecular biology reagents and services are supplied to biotech industries.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Native Antigen

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Native Antigen

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Native Antigen Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Native Antigen

Native Antigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nautilus Biotechnology, Somalogic, ProteinSimple, Amunix and Dynamic Biosensors, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
A proteomics platform is developed for analyzing the human proteome.
domain founded_year HQ Location
Protein-based assays are developed for life science research.
domain founded_year HQ Location
Provider tools to help researchers with protein analysis
domain founded_year HQ Location
Peptide-based therapeutics are developed for cancers and immune disorders.
domain founded_year HQ Location
Label-free solutions for molecular interactions and biophysical analysis are provided.
domain founded_year HQ Location
Proteomics services are delivered via discovery and targeted platforms.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Native Antigen

Frequently Asked Questions about Native Antigen

When was Native Antigen founded?

Native Antigen was founded in 2010.

Where is Native Antigen located?

Native Antigen is headquartered in Upper Heyford, United Kingdom. It is registered at Upper Heyford, England, United Kingdom.

Is Native Antigen a funded company?

Native Antigen is a funded company, having raised a total of $1.1M across 5 funding rounds to date.

How many employees does Native Antigen have?

As of Jul 31, 2020, the latest employee count at Native Antigen is 28.

What does Native Antigen do?

Founded in 2010, Native Antigen is based in Upper Heyford, United Kingdom, and operates in the biotechnology sector. Native and recombinant viral and bacterial antigens are developed and manufactured for use by pharmaceutical and in vitro diagnostic manufacturers in vaccine research and serology applications, where proper folding and glycosylation are required. Bespoke product development and custom manufacturing are also undertaken using a proprietary mammalian cell protein expression system.

Who are the top competitors of Native Antigen?

Native Antigen's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.

What products or services does Native Antigen offer?

Native Antigen offers Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits.

Who are Native Antigen's investors?

Native Antigen has 2 investors. Key investors include Mercia, and LGC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available